Articles

Learn key changes in the AMCP Dossier 5.0 format.
Currently, Medicaid rebates paid by drug manufacturers are capped at the quarterly Average Manufacturer’s Price (AMP) for each drug/biologic. The removal of the cap means ...
Today there is a laser focus on product performance out of the gate, so there is a lot of pressure to get it right. This means pharma companies need to make sure that they have the right launch team in place before putting together the structure and tactics in their launch plans. Read to learn more.
How can reps engage physicians beyond office visits in our digital world? Ultimately, this is what the launch teams need to answer when developing the ‘how to execute’ portion of their strategies.
Pharma companies that have product launches that repeatedly perform beyond expectations know how to develop vision and positioning, create a brand strategy with notable differentiation, and focus on building superior customer experiences. Learn more.
At Herspiegel, we have partnered with biotech and pharma companies big and small and have successfully brought millions of dollars worth of drugs, devices, and treatments to market. But before we get a product out the door, we help launch teams navigate their go-to-market strategies.
Read the article about the cost and supply challenges leading to Hospitals needing to start their own drug companies to lower generic drug prices.
Complete Response Letters (CRLs) are increasing. How are pharma companies preparing? Read more.
In this post, we discuss different approaches that aim to incite competition between branded and generic drug products, as well as an example demonstrating the potential impact of these policies.
This is the first in a four-part series where we will explore the issue of government intervention in drug costs. In this first post, we introduce a few commonly mentioned tactics, two of which we will dig deeper into in subsequent posts.
A recent pivotal Phase 3 clinical trial marked a significant milestone for our client, a biopharmaceutical company, in their quest to introduce a novel treatment for major depressive disorder (MDD). Read more.
Explore Herspiegel's expert strategies for successful rare disease launches, from tech innovation to market responsiveness. Learn more now.
The Centers for Medicare & Medicaid Services (CMS) just announced the first set of drugs and biologics for price negotiations to be effective 2026. Read the article to find out more.
Since CMS announced the first ten drugs selected for price negotiation on August 29th, 2023, primary manufacturers had until October 1st, 2023, to sign agreements to participate in the Price Negotiation Program. Read the article to find out more.
Master drug launch success! Herspiegel shares 4-part blog series on de-risking launch plans. Tap into our go-to-market model now.
Maximize portfolio impact! Learn key co-positioning strategies for products in our latest whitepaper. Boost performance now.
Transform patient outcomes with effective support programs. Learn how to create impactful adherence strategies—start now!
Master oncology product launches with key strategies for success. Learn vital planning & collaboration tips. Watch our presentation.
Discover cell & gene therapy launch secrets with Beth Schurman & Kate Reedy on Herspiegel Conversations. Watch now.
Uncover how the Inflation Reduction Act revolutionizes Medicare & drug prices. Stay ahead with Herspiegel's insights. Read now.
Navigate pharma's complex landscape with Herspiegel’s savvy drug launch forecasting. Discover strategies for success. Click to learn more.
Discover the vast impact of rare diseases affecting 30M Americans & the struggle for diagnosis. Dive deeper into their stories.
Uncover how Executive Order 14091 transforms healthcare for underserved communities & what it means for manufacturers. Learn more.
Discover top strategies for successful patient services in chronic conditions. Watch our presentation for key insights & case study.
Learn how to build holistic patient support with insights from Herspiegel & Courier Health. Unlock secrets to patient-centric care now.
Discover the latest in patient support trends with Brian Torres in this insightful interview. Visit our Hub for more exclusive resources.
Gain insights into creating successful patient support programs. Access our exclusive presentations, whitepapers, and case studies. Sign in today.
Explore 5 key strategies the Build Back Better Act employs to cut drug costs. Essential insights for pharma strategy. Click to learn more.